The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009. The BPCIA provides for a regulatory approval pathway for biosimilar products, which are like generic pharmaceuticals in that they are based on already approved 'name brand' biologics.
Click here to access full article
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
